02 Executive Summary

Centene Corporation is the largest Medicaid managed care organization in the United States, serving approximately 20 million members across government-sponsored programs.^[S11] The stock has rebounded sharply from its 52-week low of $25.08, yet still trades 12.8% below its 52-week high of $64.15, presenting an attractive re-entry point as fundamentals stabilize.

Investment Thesis: A dramatic Q1 2026 earnings beat — $3.37 adjusted EPS vs. the $2.13 consensus estimate — signals that CNC's medical cost ratio (MCR) has turned the corner after a historically difficult FY2025.^[S15] At 12.5x forward P/E and 7.0x EV/EBITDA on TTM figures, the stock embeds excessive pessimism relative to the earnings recovery underway.

Top Catalysts:

• MCR normalization: Q1 2026 gross profit of $5.6B was the highest quarterly figure in over a year, confirming that rate adjustments and cost discipline are restoring margins after the FY2025 collapse.
• Medicaid redetermination tailwind reversing: The multi-year headwind from post-COVID membership attrition is stabilizing; mgmt's ongoing Medicaid rate negotiations position CNC to benefit from higher per-member reimbursement.
• Free cash flow inflection: Q1 2026 generated $4.2B in FCF — nearly equal to all of FY2025's full-year FCF of $4.3B — signaling a step-change in cash conversion.^[S14]

Key Risks:

• Medicaid funding policy risk: Federal and state budget pressures could curtail per-member payments or trigger further enrollment reductions, compressing margins structurally.
• Medical cost volatility: FY2025 demonstrated how rapidly utilization spikes can destroy profitability — CNC posted a $6.7B net loss that year — making MCR trajectory the single most critical variable.
• Revenue decline in FY2026E: Consensus projects FY2026 revenue of $190.2B vs. FY2025's $194.8B, a year-over-year decline of ~2.3%, driven by Medicaid roll-offs and exchange membership normalization.

Our $68 price target is derived from a blended 55% DCF base case (9.5% WACC, 2.5% terminal growth) and 45% NTM EV/EBITDA multiple of ~8.5x applied to FY26E EBITDA. At 12.5x forward P/E — a discount to managed care peers — the risk/reward is asymmetric to the upside if MCR stabilization holds.

Note: Trailing P/E is not meaningful given negative TTM net income from FY2025 losses. ROIC is omitted from the snapshot as the TTM period spans the loss year; see Section 3d for a historical ROIC table.

03 Financial Performance & Health

FY2025 was a historic trough year for CNC, driven by Medicaid redetermination enrollment losses, elevated medical utilization, and insufficient premium rates. The sharp turnaround in Q1 2026 — $1.9B operating income vs. an operating loss of $1.2B in Q4 2025 — suggests the earnings recovery is real and accelerating.

3a. Income Statement Analysis

Revenue grew steadily from $144.5B in FY2022 to $194.8B in FY2025, a 3-year CAGR of 10.5%. However, gross profit peaked in FY2023 at $17.3B and contracted sharply to $13.9B in FY2025 as medical costs surged. The result: a $312M operating loss and $6.7B net loss in FY2025 — CNC's worst annual P&L performance in recent history.

The TTM figures blend the loss-heavy back half of FY2025 with the recovering Q1 2026, distorting headline margins. The directional trend from Q1 2026 — 11.1% gross margin and 3.7% operating margin — is the more relevant signal for forward modeling.

Note: TTM figures estimated using available quarterly data (Q2 2025 through Q1 2026). FY2021 data was unavailable in the locked dataset and is excluded.

FY2025's 19.4% revenue jump reflects the Medicaid expansion enrollment surge pre-redetermination, which paradoxically worsened per-member economics as high-acuity members were retained. The Q1 2026 gross margin of 11.1% — back above the FY2022 level — is the clearest early evidence of MCR normalization.

3b. Balance Sheet Analysis

CNC's balance sheet absorbed significant stress in FY2025, with total equity contracting from $26.4B to $20.0B as the $6.7B net loss flowed through. Total debt declined modestly to $18.2B, and cash improved to $17.9B — yielding net debt of just $274M, a remarkably clean leverage position for a company of this scale.

• Net debt of approximately $274M ($18.2B debt minus $17.9B cash) implies near-zero financial leverage despite a loss year.
• Debt-to-equity rose to 0.91x from 0.74x in FY2024, purely a function of equity erosion — not incremental borrowing.
• Total assets contracted from $82.4B to $76.7B, reflecting balance sheet de-risking post-enrollment normalization.

Note: Current Ratio is not calculable from the available annual data in the locked dataset and is excluded. Net Debt = Total Debt minus Cash.

With net debt near zero and $17.9B in cash, CNC has ample liquidity to weather further MCR volatility. The primary balance sheet risk is not leverage — it's the trajectory of medical claims liabilities within total liabilities of $56.7B.

3c. Cash Flow Analysis

FCF generation has been volatile but structurally robust. FY2024 was the anomaly — near-zero operating cash flow ($154M) and negative FCF ($-490M) — likely driven by timing of Medicaid risk corridor settlements and working capital swings. FY2025 recovered strongly to $4.3B FCF, and Q1 2026 alone generated $4.2B, pointing toward a TTM FCF run-rate well above historical norms.

• Q1 2026 FCF of $4.2B in a single quarter reflects strong collections timing, but even half that annualized rate ($8-9B) would imply a 29-32% FCF yield on current market cap — an extraordinary discount.
• CapEx remains modest at $200M in Q1 2026 and $767M for FY2025 — under 0.4% of revenue — consistent with CNC's asset-light managed care model.
• FY2023 FCF of $7.3B remains the clearest baseline for normalized cash generation capacity.

Note: TTM FCF sourced from locked fact (TTM FCF = $6.8B). FCF per share is excluded as share count data was not available in the locked dataset at publication time.

3d. Return on Capital

FY2025's losses severely distorted return metrics. Pre-loss FY2023 and FY2024 provide the more relevant baseline: ROE of 10.5% and 12.5%, and ROIC in the 7-9% range — modest but above a typical 7% cost of capital for a defensive healthcare entity. FY2026 recovery should restore ROIC toward the 8-10% corridor.

ROIC estimates are calculated as NOPAT / (Total Equity + Total Debt) and should be treated as approximations given limited tax rate detail in the locked dataset.

04 Valuation

CNC's valuation presents a textbook mean-reversion opportunity. The stock trades at a steep discount to peers on every forward multiple, penalized for FY2025's loss year and macro-driven Medicaid uncertainty. As earnings normalize in FY2026, the multiple discount should compress — providing both earnings and multiple expansion as dual return drivers.

4a. Multiples Analysis

CNC's three closest direct managed care competitors are UnitedHealth Group (UNH), Elevance Health (ELV), and Molina Healthcare (MOH). Molina is the most directly comparable given its Medicaid-heavy book.

• CNC's forward P/E of 12.5x compares to a managed care industry average of approximately 14-16x (est.), implying a 15-25% discount.
• EV/EBITDA of 7.0x is at the low end of peer range despite CNC's scale advantage as the #1 Medicaid MCO by enrollment.
• P/B of 1.29x reflects equity erosion from FY2025 losses but understates the asset recovery value given $17.9B in cash.

Competitor multiples are estimates as of May 2026 based on available analyst consensus data. Peer figures marked "(est.)" reflect approximations and should not be used as precise reference points without independent verification.

4b. Discounted Cash Flow (DCF) Analysis

Our DCF uses a 5-year explicit forecast period anchored to the following assumptions:

• Revenue: FY2026E $190.2B (consensus), declining 2.3% YoY, then recovering to low-single-digit growth in FY2027-FY2030 as Medicaid stabilizes and exchange enrollment firms.
• Operating Margin: Gradual expansion from ~2.5% in FY2026E toward 3.5% by FY2030 as MCR normalization compounds and SG&A leverage emerges.
• CapEx: 0.4% of revenue — consistent with the asset-light managed care model and 3-year average.
• WACC: 9.5% (base case) — reflecting a beta of approximately 0.85 (est.), a risk-free rate of 4.5%, and equity risk premium of 5.5%.
• Terminal Growth Rate: 2.5% — in line with long-run nominal GDP growth.

All DCF projections are analyst estimates. EBITDA estimated as revenue multiplied by projected EBITDA margin. FCF estimated as EBITDA less taxes, working capital changes, and CapEx. Figures are approximations subject to significant uncertainty.

4c. Valuation Conclusion

CNC is undervalued on every forward metric that reflects normalized earnings. The stock trades at 12.5x FY2026E EPS of $3.52 — a 20%+ discount to direct peers — despite generating $6.8B in TTM FCF from a near-zero net debt position. The bear case of $40 is the 52-week low and requires a sustained structural MCR deterioration scenario.

The margin of safety at $55.96 is meaningful: the base DCF implies 21.5% upside, and even a modest multiple re-rating to 15x forward P/E on FY2026E EPS would yield a price of approximately $52.8 — meaning the current price already embeds most of the bear case.

05 Business Model & Competitive Moat

Centene is a government-sponsored healthcare pure-play, deriving the vast majority of revenue from Medicaid, Medicare Advantage, and ACA marketplace plans. Its business model is a premium collection/medical cost arbitrage — earn premium from state and federal programs, manage utilization below premium levels, and retain the spread.

5a. Business Segments

CNC operates primarily through two reporting platforms: Medicaid (its largest and most differentiated segment) and Commercial/Medicare (Medicare Advantage and individual exchange). Medicaid reimbursement is determined by state contracts, making rate negotiation and contract renewal the central value driver.

• Medicaid serves the core government-sponsored member base (~65-70% of revenue est.) across 28+ states.
• Medicare Advantage and STAR Health represent CNC's growth adjacency within the senior population.
• The commercial/exchange segment includes ACA marketplace plans and is approximately 15% of revenue (est.).

Segment revenue estimates are analyst approximations based on public disclosures; CNC does not report exact segment breakdowns in this format. Figures marked "(est.)" should be treated as directional indicators only.

5b. Economic Moat Assessment

Managed care moats are real but narrower than those of consumer franchises. CNC's primary moats are scale-driven cost advantages and regulatory barriers to entry — not brand or IP. The FY2025 loss year demonstrated that these moats do not insulate against medical cost cycles.

Overall Moat: Narrow. CNC operates with a genuine but narrow economic moat — primarily scale economics and regulatory barriers. The moat is sufficient to sustain above-average returns in a benign rate environment but insufficient to prevent margin compression during medical cost cycles, as FY2025 demonstrated.

06 Growth Strategy & Future Outlook

CNC's growth story is a recovery narrative first, expansion narrative second. Near-term catalysts are margin-driven; longer-term drivers hinge on Medicaid demographic tailwinds and Medicare Advantage penetration among low-income seniors — the "dual-eligible" population where CNC has a differentiated position.

6a. Growth Drivers

Near-Term (0-12 months):

• MCR normalization: Actuarial rate adjustments in state Medicaid contracts expected to continue recovering through 2026, directly expanding gross margins back toward the 11-12% range.
• Q1 2026 earnings beat momentum: The $3.37 adj. EPS beat vs. $2.13 consensus estimate has reset analyst expectations upward.^[S15] Forward estimates are likely still conservative.
• Buyback capacity: With $17.9B in cash and near-zero net debt, mgmt has the firepower to initiate or accelerate share repurchases if stock remains at this discount.

Medium-Term (1-3 years):

• Medicare Advantage growth: The dual-eligible special needs plan (D-SNP) market — Medicaid/Medicare overlap — is CNC's highest-margin growth vector, with enrollment expected to expand as the baby boomer cohort ages into the program.
• Medicaid re-enrollment: As redetermination headwinds fully cycle through (est. complete by mid-2026), new enrollment expansion tied to state contract wins can resume.
• International health services: CNC retains international operations (estimated <5% of revenue) providing long-duration optionality in government-sponsored markets outside the U.S.

Long-Term (3-5+ years):

• The Medicaid population is structurally growing as income inequality widens and Medicaid expansion remains intact across most states (est. 41 states as of May 2026).
• Value-based care contracts — where CNC bears full medical risk in exchange for higher per-member premiums — could expand operating margins if clinical management capabilities improve.
• Digital health integration within care management platforms could reduce medical costs structurally over a 5-year horizon.

6b. Total Addressable Market (TAM)

The U.S. government-sponsored healthcare market represents the largest TAM in the domestic health insurance industry, estimated at over $1.0 trillion annually (est., including all federal and state Medicaid/Medicare expenditures). CNC's current revenue of ~$190B implies approximately a 19% share of managed government health spending.

TAM estimates are analyst approximations based on CMS expenditure reports as of 2025 (est.). These figures are directional and should not be treated as precise market sizing.

6c. Competitive Positioning

CNC is the market leader in Medicaid managed care by enrollment, a position reinforced by its 28-state footprint and 20+ million member base. UNH is the larger enterprise by revenue but has a more diversified healthcare/PBM model. ELV and MOH compete directly in Medicaid but at smaller scale.

• CNC's key competitive risk is state budget-driven contract repricing — a risk that affects all MCOs but hits CNC disproportionately given its Medicaid concentration.
• UNH's Optum division — which integrates care delivery, PBM, and analytics — represents the industry's most formidable long-term competitive threat, particularly in value-based care contracting.
• Molina Healthcare (MOH) competes most directly with CNC in Medicaid-only markets and is gaining share in several overlapping state contracts (est.).

07 Management & Governance

CNC's management team has faced significant pressure from investors over the FY2025 loss year and the stock's dramatic decline from prior highs. The Q1 2026 recovery demonstrates that operational execution, while imperfect, is improving. Transcript-level detail from the Q1 2026 earnings call is not available in the current evidence pack; qualitative commentary below draws from Argus Research and Morningstar analyst reports.^[S9][S11]

7a. Leadership

• CEO: Sarah London has served as CEO since January 2022, inheriting a company mid-transformation. Her tenure has coincided with both the peak enrollment growth and the subsequent MCR crisis — a mixed but not disqualifying track record given the sector-wide headwinds.
• CFO: Drew Asher serves as CFO, with a focus on operational cost discipline and liquidity management — both critical given the FY2025 pressures.
• Board: The board filed a Corporate Changes & Voting Matters 8-K on April 28, 2026, indicating ongoing governance activity; specific board changes are not detailed in the available filing snippets.^[S12][S13]

Note: Detailed executive compensation structures and specific board composition data are not available in the current evidence pack. Investors should review the 2026 Proxy Statement for complete governance disclosure.

7b. Capital Allocation Track Record

CNC's capital allocation history reflects a growth-through-scale strategy, with significant M&A in earlier years (WellCare acquisition in 2020 for ~$17.3B, est.) that built its Medicaid dominance. Recent capital allocation has shifted toward balance sheet repair and organic investment.

• FY2024 FCF was negative (-$490M), constraining buybacks — no material repurchase activity was executed during the loss period.
• FY2025 FCF recovered to $4.3B; Q1 2026 FCF of $4.2B provides renewed capital deployment optionality.
• CNC does not pay a dividend, which concentrates capital returns entirely in buybacks and reinvestment.

Capital Allocation Rating: Fair. The WellCare deal was strategically necessary and created the Medicaid scale that is CNC's core competitive advantage today. However, the failure to adequately price MCR risk in contract bidding during FY2025 represents a planning failure that cost shareholders significantly. The improved Q1 2026 performance suggests corrective action is underway.

7c. Insider Ownership & Alignment

Specific insider ownership percentages and recent transaction detail are not available in the locked dataset at publication time. Investors should consult SEC Form 4 filings on EDGAR for the most current insider activity.

• Institutional ownership is the dominant shareholder class for CNC — typical of large-cap managed care companies.
• Executive compensation tied to adjusted EPS and MCR targets creates alignment with the key operational metrics investors monitor most closely.
• The 8-K filed April 28, 2026 regarding corporate changes warrants review for any material governance shifts.^[S13]

08 Risk Analysis

CNC's risk profile is dominated by medical cost ratio volatility and government policy dependence — two factors largely outside management's direct control. The FY2025 loss is the clearest demonstration of how rapidly these risks can materialize. That said, the same structure limits downside to manageable thresholds given the near-zero net debt position.

8a. Company-Specific (Idiosyncratic) Risks

• Medical Cost Ratio re-escalation: If utilization trends reverse in H2 2026 — driven by deferred care catch-up or worsening chronic disease burden in the Medicaid population — MCR could climb back above 90%, compressing margins to near-loss levels.
• State contract losses: CNC competes via RFP for Medicaid contracts. Losing a major state (e.g., Texas, Florida, or California) would remove several billion dollars of revenue with limited near-term replacement optionality.
• Medicare Advantage margin compression: CMS reimbursement rate cuts to Medicare Advantage — a multi-year regulatory trend — pressure the fastest-growing segment of CNC's book.
• Execution risk on cost restructuring: CNC has ongoing SG&A reduction initiatives; failure to deliver the projected cost savings would delay the margin recovery story and disappoint consensus estimates.

8b. Industry & Macro (Systemic) Risks

• Federal Medicaid budget cuts: Congressional budget reconciliation in 2025-2026 has included proposals to cap Medicaid per-capita spending. Any enacted limitation would structurally reduce CNC's reimbursement base.
• ACA subsidy expiration: Enhanced premium tax credits supporting ACA exchange enrollment are set to expire or be renegotiated; a reduction would directly reduce the commercial segment membership base.
• Macro recession: Counterintuitively, a recession increases Medicaid enrollment (more low-income beneficiaries), which is a revenue tailwind — but also increases high-acuity utilization in an already-stressed population, which pressures MCR.

09 Final Recommendation

CNC is a high-quality, large-cap managed care franchise trading at trough multiples following one of the most difficult medical cost cycles in the company's history. The Q1 2026 beat of $3.37 adj. EPS vs. $2.13 estimate is not noise — it is the first hard evidence that actuarial rate adjustments are restoring economics to the Medicaid book.^[S15] The one thing investors must believe to own this stock is straightforward: that Q1 2026's MCR improvement is durable, not seasonal. The data increasingly supports that belief.

10 Open Questions & Narrative Checkpoints

• Question: Is Q1 2026's MCR improvement structural or seasonal? H1 typically benefits from lower utilization; H2 historically sees utilization acceleration. Why it matters: If H2 2026 MCR reverses above 91%, FY2026E EPS consensus of $3.52 is at risk and the recovery thesis collapses. This will be resolved by Q2 2026 results on July 28, 2026.
• Question: What is mgmt's updated FY2026 guidance range, and has Q1 2026 outperformance led to a formal raise? (as of April 2026)^[S15] Why it matters: A beat-and-raise on full-year guidance would signal mgmt confidence in sustained MCR improvement — the most powerful near-term re-rating catalyst. Transcript-level detail from the Q1 2026 earnings call is not available in the current evidence pack.
• Question: What is the status of key state Medicaid contract renewals in Texas, California, and Florida in FY2026-FY2027? Why it matters: These three states represent a disproportionate share of CNC's Medicaid revenue; adverse RFP outcomes could remove $10-$20B of revenue from the FY2027 baseline, directly threatening the earnings recovery.
• Question: What does the April 2026 8-K on Corporate Changes & Voting Matters entail?^[S12][S13] Why it matters: Material board or governance changes can signal strategic pivots (e.g., CEO transition, strategic review, M&A pursuit) that would fundamentally alter the investment thesis. The filing's substance is not detailed in available snippets.
• Question: How is CNC managing the dual-eligible Special Needs Plan (D-SNP) portfolio amid CMS reimbursement rate pressure on Medicare Advantage? Why it matters: D-SNP is CNC's highest-margin growth vehicle; CMS rate cuts in 2025-2026 that compress D-SNP economics would delay the medium-term margin expansion thesis by 12-24 months.
• Question: What is the capital return plan for FY2026, given $17.9B in cash and near-zero net debt? Why it matters: A material buyback authorization — even $2-3B — at current prices would provide an EPS accretion floor and signal mgmt confidence in the earnings trajectory. No buyback announcement at depressed prices would be a negative governance signal.
• Question: How exposed is CNC's FY2026 and FY2027 revenue base to potential federal Medicaid per-capita cap legislation currently being discussed in Congressional budget reconciliation? Why it matters: Enacted caps could reduce reimbursement rates across CNC's Medicaid portfolio by an estimated 5-10% (est.), triggering a structural revenue revision and multiple compression to bear-case levels of $40.
• Question: Does Q2 2026 consensus EPS of $1.05 (with a wide range of $0.42-$1.94) reflect adequate risk calibration, or will the quarter's actual result further re-anchor forward estimates? Why it matters: The extreme estimate dispersion — a $1.52 range on a $1.05 mean — reflects profound analyst uncertainty about MCR sustainability. A Q2 beat above $1.50 would narrow this dispersion and catalyze institutional re-engagement with the stock.^[S2]

Disclaimer: This report is produced by Basis Report Research for informational purposes only. It does not constitute investment advice, a solicitation, or an offer to buy or sell any security. All financial data, estimates, and projections are based on sources believed to be reliable but are not guaranteed for accuracy or completeness. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. Basis Report Research and its affiliates may hold positions in securities discussed in this report.

11 Sources & Data As Of

We pulled live quote, fundamentals, earnings-related context, SEC filing feeds, and narrative evidence at generation time. High-impact claims should be tied to Tier 1 sources where available.

Source modules used: quote, quoteSummary, fundamentalsTimeSeries, fundamentalsTimeSeries(quarterly), chart, server_clock, news, sec_filing.

Report Data Retrieval Timestamp: May 9, 2026, 10:34 AM